oral bisphosphonates (Fosamax, etc) might decrease the risk of breast cancer

January 2010

Women are hearing that oral bisphosphonates (Fosamax, etc) might decrease the risk of breast cancer.

A new look at the Women's Health Initiative suggests one-third fewer breast cancers in postmenopausal women taking oral bisphosphonates.

Another observational study from Israel shows a similar benefit.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote